Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

1.00
+0.06306.70%
Volume:1.46M
Turnover:1.46M
Market Cap:17.07M
PE:-0.06
High:1.06
Open:0.9350
Low:0.9010
Close:0.9400
Loading ...

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert

Benzinga
·
01 Apr

BRIEF-Allarity Therapeutics Cash & Cash Receivable Balance Of $20.9 Million As Of Dec 31, Expected To Fund Operations, Including Clinical Activities Into 2027

Reuters
·
01 Apr

Allarity Therapeutics FY 2025 GAAP EPS $(15.65) Beats $(46.80) Estimate

Benzinga
·
01 Apr

Allarity Therapeutics: Enrollment in New Phase 2 Sclc Trial to Begin in Q2-Q3 2025, Fully Funded by U.S. Veterans Administration

THOMSON REUTERS
·
01 Apr

Allarity Therapeutics: Cash & Cash Receivable Balance of $20.9 Mln as of Dec 31, Expected to Fund Operations, Including Clinical Activities Into 2027

THOMSON REUTERS
·
01 Apr

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
01 Apr

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

GlobeNewswire
·
24 Mar

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

GlobeNewswire
·
17 Mar

BRIEF-Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission

Reuters
·
13 Mar

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures

MT Newswires Live
·
13 Mar

Allarity Therapeutics: Consented, Without Admitting or Denying SEC's Findings, to Entry of Administrative Cease-and-Desist Order

THOMSON REUTERS
·
13 Mar

Allarity Therapeutics Announces Final Settlement With the U.S. Securities and Exchange Commission

THOMSON REUTERS
·
13 Mar

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

GlobeNewswire
·
13 Mar

Allarity announes Phase 2 trial of stenoparib with temozolomide

TIPRANKS
·
06 Mar

Allarity Therapeutics: Announces Phase 2 Trial of Stenoparib in Combination With Temozolomide for Recurrent Small Cell Lung Cancer

THOMSON REUTERS
·
06 Mar

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

GlobeNewswire
·
06 Mar

BRIEF-Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program

Reuters
·
03 Mar

Allarity announces board authorization of $5M share repurchase program

TIPRANKS
·
03 Mar

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

THOMSON REUTERS
·
03 Mar

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

GlobeNewswire
·
03 Mar